Citation: dave, h.Et al.Risk factor analysis of 170 single-institutional contegra implantations in pulmonary position.Ann thorac surg 2011;91:195¿203.Doi: 10.1016/j.Athoracsur.2010.07.058.Earliest date of publish used for event date.Medtronic products referenced: contegra pulmonary valved conduit (pma# h020003, product code mwh).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information via literature regarding risk factor analysis of contegra implantations.All data were collected from a single center between 2001 and 2007.The study population included 170 patients (predominantly male, mean age 9 years), all of whom were implanted with medtronic contegra valved conduit.No serial numbers were provided.Among all contegra patients, adverse events included: stenosis, increased gradient measurements, severe regurgitation, calcification, outgrowth, aneurysm, endocarditis.Treatment included medication, balloon intervention or explant.Based on the available information a medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|